EntreMed, University Of New South Wales To Collaborate On Panzem Mechanisms
EntreMed has entered into a collaborative research agreement with the University of New South Wales and Children's Cancer Institute Australia for Medical Research to map pathways involved in the mechanism of action for its lead compound, 2-methoxyestradiol (2ME2 or Panzem) and analogs of 2ME2.
Research will be conducted at CCIA and UNSW under a grant awarded by the Australian Research Council (ARC).
The primary objectives of the collaboration will be to develop models of resistance to 2ME2 in order to identify key proteins that may be potential novel drug targets and to further the understanding of how 2ME2 exerts its antitumor and antiangiogenic effects. In addition, differential proteomics and functional protein assays will be utilized to identify protein pathways involved in the mechanism of action of 2ME2 and 2ME2 analogs in order to identify novel drug targets and biomarkers of response to these agents.
Mark R. Bray, Ph.D., EntreMed Vice President, Research, commented on the collaboration, "Associate Professor Maria Kavallaris and her team at CCIA and UNSW are leaders in the study of microtubule targeting agents. Through this research, we expect to determine the relative importance of known 2ME2 mechanisms, as well as identify new protein targets and pathways whose functions are essential for the action of 2ME2 and its analogs.
Further identification of these pathways may help in selecting the most effective clinical indications for 2ME2 treatment, and may lead to the discovery of biomarkers useful for assessing 2ME2 activity in the clinic. Additionally, we hope to identify novel targets for new cancer drug development. 2ME2 (Panzem NCD) is currently in multiple Phase 1 and 2 clinical trials for the treatment of cancer."